Base-editing hematopoietic stem cell and T cell gene therapy for CD40L-HyperIgM Syndrome
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Base-editing hematopoietic stem cell and T cell gene therapy for CD40L-HyperIgM Syndrome, covering 2026-03-27 to 2026-03-27. Get the full timeline:
Most recent: Clinical Trial Update: Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study [Phase 1, Phase 2]